Griffin Asset Management’s Vivos Therapeutics VVOS Stock Holding History

Griffin Asset Management’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,808	Closed	-$188K	–	231
2022 Q1	$188K	Buy	2,808 +1,088	+63%	+$71.1K	0.02%	219
2021 Q4	$97K	Sell	1,720 -260	-13%	-$20.9K	0.01%	232
2021 Q3	$200K	Hold	1,980	–	–	0.03%	227
2021 Q2	$245K	Sell	1,980 -408	-17%	-$66.5K	0.03%	225
2021 Q1	$396K	Buy	+2,388	New	+$426K	0.05%	187

Other funds holding VVOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Griffin Asset Management's VVOS Position: Q2 2022 in Review

Griffin Asset Management sold out of Vivos Therapeutics (VVOS) in Q2 2022, closing a stake of 2,808 shares — an estimated $188K sold.

Griffin Asset Management first reported a position in VVOS in Q1 2021 and held it in 5 quarters. The position peaked at $396K in Q1 2021. 27 funds tracked by Wall St. Rank hold VVOS as of Q2 2022.

Griffin Asset Management reported no remaining Vivos Therapeutics position as of Q2 2022 after selling out during the quarter.
Griffin Asset Management sold 2,808 Vivos Therapeutics shares in Q2 2022, an estimated $188K.
Griffin Asset Management first reported a position in Vivos Therapeutics in Q1 2021 and held it in 5 quarters.
Griffin Asset Management's Vivos Therapeutics position peaked at $396K in Q1 2021.
27 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2022.

Based on Griffin Asset Management's 13F filing for Q2 2022, filed 19 Jul 2022.